The future of Escherichia coli vaccines in prevention of recurrent Urinary Tract Disease based on the newest guidelines worldwide.

Abstract

Background: Recurrent urinary tract infections (rUTIs), primarily caused by uropathogenic Escherichia coli (UPEC), pose a major global burden. Rising antimicrobial resistance creates an urgent need for non-antibiotic prophylactic strategies, accelerating interest in immunotherapeutics and vaccines. Aim: To evaluate the clinical standing of E. coli immunoprophylaxis in rUTI management under updated 2026 global guidelines, synthesize trial data on historical bacterial extracts, address methodological challenges, and explore emerging target-specific vaccines. Methods: A narrative literature search was conducted using PubMed and Google Scholar for English- and Polish-language studies published up to May 2026, targeting keywords such as "OM-89", "Uro-Vaxom", "E. coli immunotherapy", and "recurrent UTI". Eligible literature included randomized controlled trials, observational studies, systematic reviews, preclinical models, and clinical guidelines. Results: UPEC relies on type 1 fimbrial adhesin (FimH) to adhere to bladder uroepithelium and form intracellular bacterial communities (IBCs). Clinically, the oral extract Uro-Vaxom (OM-89) has historically reduced rUTI frequency and dysuria. However, study heterogeneity and inconsistent outcomes led the European Association of Urology (EAU) to downgrade OM-89's recommendation from strong to weak in 2026. Concurrently, novel subunit vaccines targeting FimH (e.g., adjuvanted FimCH) show promising safety and immunogenicity in early trials, paving the way for Phase 2 evaluation. Conclusions: While OM-89 remains a key non-antibiotic option, updated guidelines highlight the need for standardized, high-quality trials to confirm its efficacy. Next-generation FimH subunit vaccines offer a targeted immunotherapeutic strategy to break the rUTI cycle without driving antimicrobial resistance.